Related Experiment Video
Updated: Jul 15, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Dopa-responsive camptocormia in a patient with multiple system atrophy.
In-Uk Song1, Joong-Seok Kim, Kwang-Soo Lee
1Department of Neurology, College of Medicine, The Catholic University of Korea, South Korea.
Parkinsonism & Related Disorders
|April 17, 2007
Summary
Camptocormia, a severe trunk flexion in parkinsonism, typically responds poorly to levodopa. However, this case shows significant improvement in camptocormia and parkinsonian symptoms with levodopa in multiple system atrophy.
Area of Science:
- Neurology
- Movement Disorders
Background:
- Camptocormia, characterized by severe trunk anteroflexion, is a recognized but often refractory symptom in parkinsonian syndromes.
- It is typically associated with minimal or no response to levodopa treatment, posing a diagnostic and therapeutic challenge.
Observation:
- A 47-year-old patient presented with multiple system atrophy (MSA) exhibiting predominant parkinsonism and significant camptocormia.
- The patient's trunk flexion was markedly relieved upon assuming a lying position.
Findings:
- Contrary to typical presentations, the patient experienced substantial improvement in both camptocormia and parkinsonian motor symptoms following levodopa administration.
- This suggests a potential for levodopa responsiveness in specific subtypes of MSA-associated camptocormia.
Implications:
- This case challenges the conventional understanding of levodopa refractoriness in parkinsonism-related camptocormia.
- It highlights the importance of considering levodopa treatment even in the presence of severe camptocormia, particularly in suspected cases of multiple system atrophy.
- Further research may elucidate specific pathophysiological mechanisms underlying levodopa-responsive camptocormia in MSA.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...